A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal
- PMID: 16394083
- DOI: 10.1210/jc.2005-2064
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal
Abstract
Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal.
Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal.
Design, setting, and patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal.
Interventions: INTERVENTIONS included administration of rhTSH on L-T4 and withdrawal from thyroid hormone.
Main outcome measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache.
Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P < 0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively.
Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.
Similar articles
-
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.Thyroid. 2010 Feb;20(2):173-9. doi: 10.1089/thy.2009.0187. Thyroid. 2010. PMID: 20151824 Clinical Trial.
-
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.J Clin Endocrinol Metab. 2003 Sep;88(9):4110-5. doi: 10.1210/jc.2003-030298. J Clin Endocrinol Metab. 2003. PMID: 12970272 Clinical Trial.
-
Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).J Clin Endocrinol Metab. 1994 Jan;78(1):188-96. doi: 10.1210/jcem.78.1.8288703. J Clin Endocrinol Metab. 1994. PMID: 8288703 Clinical Trial.
-
Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.J Endocrinol Invest. 1999;22(11 Suppl):8-16. J Endocrinol Invest. 1999. PMID: 10727000 Review.
-
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830. Endocr Relat Cancer. 2005. PMID: 15788638 Review.
Cited by
-
Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme.Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1179-88. doi: 10.1007/s00259-015-3022-9. Epub 2015 Mar 13. Eur J Nucl Med Mol Imaging. 2015. PMID: 25771905 Free PMC article.
-
Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin.Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):363-7. doi: 10.1007/s00259-006-0227-y. Epub 2006 Sep 22. Eur J Nucl Med Mol Imaging. 2007. PMID: 17021814
-
Expanding indications for recombinant human TSH in thyroid cancer.Thyroid. 2008 Jul;18(7):687-94. doi: 10.1089/thy.2008.0162. Thyroid. 2008. PMID: 18630995 Free PMC article. No abstract available.
-
Differentiated thyroid cancer-personalized therapies to prevent overtreatment.Nat Rev Endocrinol. 2014 Sep;10(9):563-74. doi: 10.1038/nrendo.2014.100. Epub 2014 Jul 1. Nat Rev Endocrinol. 2014. PMID: 24981455 Review.
-
Quality of Life and Cost-Effectiveness of Radiofrequency Ablation versus Open Surgery for Benign Thyroid Nodules: a retrospective cohort study.Sci Rep. 2016 Nov 24;6:37838. doi: 10.1038/srep37838. Sci Rep. 2016. PMID: 27883069 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical